Comparable stake leader
Bradford T. Whitmore
SEC ownership of Clearside Biomedical, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001539029.
Disclosed value leader
Bradford T. Whitmore
Comparable rows
2/14
Latest evidence
31 Mar 2025
- Public ticker
- CLSDQ on OTC
- Parsed ownership sources
-
3/4/5 and 13D/G
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Bradford T. Whitmore
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
2 of 14
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Bradford T. Whitmore
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
31 Mar 2025
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001539029
- Issuer location
- Alpharetta, GA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Clearside Biomedical, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Bradford T. Whitmore
Disclosed value leader
Bradford T. Whitmore
Comparable rows
2/14
Latest evidence
31 Mar 2025
3/4/5
13D/G
Lead comparable stake: 8.6%
12 rows are not safely comparable across share classes.
13D/G row: Bradford T. Whitmore
Showing 1-8 of 14 holder rows.
Quick read
Bradford T. Whitmore leads the comparable SEC ownership view at 8.6%.
2 of 14 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Bradford T. Whitmore's linked filing trail.
Comparable ownership
Top 2
Bradford T. Whitmore
8.6%
Stephen Boyd Wiles
5.2%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 14 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Bradford T. Whitmore |
3/4/5
13D/G
10%+ Owner · WHITMORE BRADFORD T
|
8.6%
from 13D/G
|
$9,241,001
7,289,630 shares
mixed-class rows
|
— | 07 Feb 2024 |
| Stephen Boyd Wiles |
13D/G
|
5.2%
|
$3,362,985
4,003,553 shares
|
$0 | 31 Mar 2025 |
| George M. Lasezkay |
3/4/5
CEO, Director
|
—
mixed-class rows
|
$592,553
1,406,077 shares
mixed-class rows
|
— | 08 Jan 2025 |
| Charles A. Deignan |
3/4/5
Chief Financial Officer
|
—
mixed-class rows
|
$488,521
784,662 shares
mixed-class rows
|
— | 08 Jan 2025 |
| Thomas Ciulla |
3/4/5
Chief Medical Officer
|
—
class O/S missing
|
$370,700
291,890 shares
|
— | 20 Jan 2023 |
| Clay Thorp |
3/4/5
Director
|
—
mixed-class rows
|
$162,050
221,141 shares
mixed-class rows
|
— | 24 Feb 2025 |
| Anthony S. Gibney |
3/4/5
Director
|
—
mixed-class rows
|
$130,000
145,000 shares
mixed-class rows
|
— | 20 Jun 2024 |
| Nancy J. Hutson |
3/4/5
Director
|
—
mixed-class rows
|
$118,110
138,000 shares
mixed-class rows
|
— | 20 Jun 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 05 Sep 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-13 of 13 reporting-owner rows connected to Clearside Biomedical, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
13
Largest Forms 3/4/5 holder
Bradford T. Whitmore
Net 12M change
$0
Latest report
24 Feb 2025
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Bradford T. Whitmore | 10%+ Owner | $9,241,001 | Mixed | 07 Feb 2024 | ||
| George M. Lasezkay | CEO, Director | $592,553 | Filing P/S | 08 Jan 2025 | ||
| Charles A. Deignan | Chief Financial Officer | $488,521 | Filing P/S | 08 Jan 2025 | ||
| Thomas Ciulla | Chief Medical Officer | $370,700 | Mixed | 20 Jan 2023 | ||
| Clay Thorp | Director | $162,050 | Filing P/S | 24 Feb 2025 | ||
| Anthony S. Gibney | Director | $130,000 | Filing P/S | 20 Jun 2024 | ||
| Nancy J. Hutson | Director | $118,110 | Mixed | 20 Jun 2024 | ||
| Ngai Hang Victor Chong | Chief Medical Officer | $100,000 | Filing P/S | 08 Jan 2025 | ||
| William D. Humphries | Director | $64,821 | Mixed | 20 Jun 2024 | ||
| Benjamin R. Yerxa | Director | $23,524 | Filing P/S | 20 Jun 2024 | ||
| Richard Croarkin | Director | Mixed | 20 Jun 2024 | |||
| Jeffrey L. Edwards | Director | Mixed | 20 Jun 2024 | |||
| Christy L. Shaffer | Director | Mixed | 20 Jun 2024 |
Recent insider transactions for Clearside Biomedical, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* marks a reported price that did not pass the local price check.